John S Yu bought $5,760 of KAPA
CEO and Chairman at Kairos Pharma, LTD.. 4,000 shares at an average of $1.44, traded Nov 20, 2024, filed Nov 21, 2024.
Score components
- +25RoleCEO
- 0Trade size$6k at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.7%, 3m -11.3%, 6m -62.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-047261, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | POpen-market purchase COMMON STOCK | +4,000 | $1.44 | $5,760 | 5,341,837 | Nov 21, 2024 |
Related signals
Other insiders at Kairos Pharma, LTD. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Kairos Pharma, LTD. | Doug Samuelson Chief Financial Officer | $3,750 2,500 shares | +4% | |
| 25Weak | Kairos Pharma, LTD. | Ramachandran Murali VP of Research and Development | $318 200 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.